Safety and usefulness of intravenous iron sucrose in the management of preoperative anemia in patients with menorrhagia: A phase iv, open-label, prospective, randomized study

Yun Hwan Kim, Hyun Hoon Chung, Soon Beom Kang, Seung Cheol Kim, Young Tae Kim

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Background: The aim of this study was to compare the efficacy, safety and achievement of the target hemoglobin level (Hb ≥10 g/dl) in patients with preoperative anemia due to menorrhagia who received intravenous iron sucrose compared with oral iron protein succinylate for anemia management. Methods: Seventy-six patients with Hb levels <9.0 g/dl who were scheduled to undergo surgical treatment were randomized to receive either intravenous iron sucrose (based on the calculated total iron deficit divided into 2 ampoule infusions intravenously 3 times a week, beginning 3 weeks before surgery) or oral iron (80 mg/day of oral iron protein succinylate daily). Results: The intravenous iron group had higher increases in Hb (3.0 vs. 0.8 g/dl; p < 0.0001) and ferritin levels (170.1 vs. 4.1 μg/l; p < 0.0001) than the oral iron group. Achieving the target Hb was also higher in the intravenous iron group than in the oral iron group (76.7 vs. 11.5%; p < 0.0001). There were tolerable adverse events in both groups. Conclusion: Preoperative intravenous iron sucrose administration is more effective than oral iron and is as safe as oral iron therapy in the correction of preoperative anemia due to menorrhagia.

Original languageEnglish
Pages (from-to)37-41
Number of pages5
JournalActa Haematologica
Volume121
Issue number1
DOIs
Publication statusPublished - 2009 Apr 1

Fingerprint

saccharated ferric oxide
Menorrhagia
Anemia
Iron
Prospective Studies
Safety
iron protein succinylate
Oral Surgery
Ferritins

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

@article{100e23f0c6c64128abcb93846380cf5c,
title = "Safety and usefulness of intravenous iron sucrose in the management of preoperative anemia in patients with menorrhagia: A phase iv, open-label, prospective, randomized study",
abstract = "Background: The aim of this study was to compare the efficacy, safety and achievement of the target hemoglobin level (Hb ≥10 g/dl) in patients with preoperative anemia due to menorrhagia who received intravenous iron sucrose compared with oral iron protein succinylate for anemia management. Methods: Seventy-six patients with Hb levels <9.0 g/dl who were scheduled to undergo surgical treatment were randomized to receive either intravenous iron sucrose (based on the calculated total iron deficit divided into 2 ampoule infusions intravenously 3 times a week, beginning 3 weeks before surgery) or oral iron (80 mg/day of oral iron protein succinylate daily). Results: The intravenous iron group had higher increases in Hb (3.0 vs. 0.8 g/dl; p < 0.0001) and ferritin levels (170.1 vs. 4.1 μg/l; p < 0.0001) than the oral iron group. Achieving the target Hb was also higher in the intravenous iron group than in the oral iron group (76.7 vs. 11.5{\%}; p < 0.0001). There were tolerable adverse events in both groups. Conclusion: Preoperative intravenous iron sucrose administration is more effective than oral iron and is as safe as oral iron therapy in the correction of preoperative anemia due to menorrhagia.",
author = "Kim, {Yun Hwan} and Chung, {Hyun Hoon} and Kang, {Soon Beom} and Kim, {Seung Cheol} and Kim, {Young Tae}",
year = "2009",
month = "4",
day = "1",
doi = "10.1159/000210062",
language = "English",
volume = "121",
pages = "37--41",
journal = "Acta Haematologica",
issn = "0001-5792",
publisher = "S. Karger AG",
number = "1",

}

Safety and usefulness of intravenous iron sucrose in the management of preoperative anemia in patients with menorrhagia : A phase iv, open-label, prospective, randomized study. / Kim, Yun Hwan; Chung, Hyun Hoon; Kang, Soon Beom; Kim, Seung Cheol; Kim, Young Tae.

In: Acta Haematologica, Vol. 121, No. 1, 01.04.2009, p. 37-41.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Safety and usefulness of intravenous iron sucrose in the management of preoperative anemia in patients with menorrhagia

T2 - A phase iv, open-label, prospective, randomized study

AU - Kim, Yun Hwan

AU - Chung, Hyun Hoon

AU - Kang, Soon Beom

AU - Kim, Seung Cheol

AU - Kim, Young Tae

PY - 2009/4/1

Y1 - 2009/4/1

N2 - Background: The aim of this study was to compare the efficacy, safety and achievement of the target hemoglobin level (Hb ≥10 g/dl) in patients with preoperative anemia due to menorrhagia who received intravenous iron sucrose compared with oral iron protein succinylate for anemia management. Methods: Seventy-six patients with Hb levels <9.0 g/dl who were scheduled to undergo surgical treatment were randomized to receive either intravenous iron sucrose (based on the calculated total iron deficit divided into 2 ampoule infusions intravenously 3 times a week, beginning 3 weeks before surgery) or oral iron (80 mg/day of oral iron protein succinylate daily). Results: The intravenous iron group had higher increases in Hb (3.0 vs. 0.8 g/dl; p < 0.0001) and ferritin levels (170.1 vs. 4.1 μg/l; p < 0.0001) than the oral iron group. Achieving the target Hb was also higher in the intravenous iron group than in the oral iron group (76.7 vs. 11.5%; p < 0.0001). There were tolerable adverse events in both groups. Conclusion: Preoperative intravenous iron sucrose administration is more effective than oral iron and is as safe as oral iron therapy in the correction of preoperative anemia due to menorrhagia.

AB - Background: The aim of this study was to compare the efficacy, safety and achievement of the target hemoglobin level (Hb ≥10 g/dl) in patients with preoperative anemia due to menorrhagia who received intravenous iron sucrose compared with oral iron protein succinylate for anemia management. Methods: Seventy-six patients with Hb levels <9.0 g/dl who were scheduled to undergo surgical treatment were randomized to receive either intravenous iron sucrose (based on the calculated total iron deficit divided into 2 ampoule infusions intravenously 3 times a week, beginning 3 weeks before surgery) or oral iron (80 mg/day of oral iron protein succinylate daily). Results: The intravenous iron group had higher increases in Hb (3.0 vs. 0.8 g/dl; p < 0.0001) and ferritin levels (170.1 vs. 4.1 μg/l; p < 0.0001) than the oral iron group. Achieving the target Hb was also higher in the intravenous iron group than in the oral iron group (76.7 vs. 11.5%; p < 0.0001). There were tolerable adverse events in both groups. Conclusion: Preoperative intravenous iron sucrose administration is more effective than oral iron and is as safe as oral iron therapy in the correction of preoperative anemia due to menorrhagia.

UR - http://www.scopus.com/inward/record.url?scp=63049092549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63049092549&partnerID=8YFLogxK

U2 - 10.1159/000210062

DO - 10.1159/000210062

M3 - Article

C2 - 19332985

AN - SCOPUS:63049092549

VL - 121

SP - 37

EP - 41

JO - Acta Haematologica

JF - Acta Haematologica

SN - 0001-5792

IS - 1

ER -